Stocks · News reference
8-K filing — CAPRICOR THERAPEUTICS, INC. (CAPR)
Filed: 2026-08-24 AccNo: 0001104659-26-100071 Size: 174 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Nasdaq Composite falling around 1% on Tuesday. Shares of Yext Inc (NYSE:YEXT) rose sharply after the company reported better-than-expected second-quarter earnings. The company also
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role
Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Capricor Therapeutics, Pentair plc, and Bloom Energy Corporation on behalf of investors who suffered losses. The primary case involves Capricor, where the FDA released briefing documents revealing that the company made undisclosed changes to its statistical analysis plan for a drug application, resulting in a 64% stock price drop on July 27, 2026.